Group 1 - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., will hold its third extraordinary general meeting of shareholders on December 5, 2025, as decided in the 24th meeting of the fifth board of directors [1][31] - The meeting will combine on-site voting and online voting, with specific time slots for each voting method [2][3] - Shareholders must register to attend the meeting between December 2 and December 3, 2025, and can delegate representatives to vote on their behalf [11][12] Group 2 - The board of directors has approved the termination of the 2025 restricted stock and stock option incentive plan due to the company's inability to complete the necessary registration and announcement within the stipulated 60 days [27][35] - The decision to terminate the incentive plan was made after considering the current operational situation and market conditions, ensuring it does not negatively impact the company's financial status or shareholder interests [36][37] - The company will not propose a new incentive plan for three months following the announcement of the termination [36]

Core Points - The company *ST Shuangcheng (002693.SZ)* announced a restricted stock and stock option incentive plan for 2025, proposing to grant a total of 20 million stock rights, accounting for 4.82% of the company's total share capital of 414.68975 million shares at the time of the announcement [1] Group 1 - The incentive plan includes a restricted stock grant of 12 million shares, representing 2.89% of the total share capital [1] - The stock option grant proposed in the plan is 8 million shares, which is 1.93% of the total share capital [1] - The grant price for the restricted stock is set at 3.97 yuan per share, while the exercise price for the stock options is 7.93 yuan per share [1] Group 2 - A total of 149 individuals will be granted the incentives, including directors, senior management, middle management, and key technical (business) personnel, excluding independent directors and shareholders holding more than 5% of shares [1] - The validity period for the restricted stock is from the completion of the grant registration until all restrictions are lifted or the stock is repurchased, lasting no more than 48 months [2] - The validity period for the stock options is similarly set from the completion of the grant registration until all options are exercised or canceled, also lasting no more than 48 months [2]